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Genetic Regulation of Mammary
Carcinogenesis in the Rat by Susceptibility
and Suppressor Genes
by Michael N. Gould* and Rong Zhang*
Rat strains differ in their susceptibilities to mammary carcinogenesis. Strains such as Wistar-Furth are
very susceptible to chemically induced carcinogenesis. This phenotype is controlled by autosomally dom-
inant susceptibility genes. Strains such as the Copenhagen are resistant to spontaneous and induced
mammary carcinogenesis. This phenotype is controlled by an autosomal dominant gene termed the mam-
mary carcinoma suppressor (MCS). Strains with intermediate susceptibility such as the F344 carry neither
the MCS nor susceptibility genes. Both the MCS and susceptibility genes are chiefly active within the
mammary parenchyma. Both genes act at carcinogenesis stages beyond carcinogen metabolism and DNA
adduction. TheMCS gene completely inhibits both palpable and microcarcinomas. It does not inhibit focal
alveolar hyperplasias. Its gene product acts solely within the mammary epithelial cell in which it is
produced. We are currently investigating the interactions of various oncogenes and the MCS gene. In
addition, efforts are underway to identify and clone this gene.
Introduction
Genetic predisposition to breast canceris amajorrisk
factor in women. Factors contributing to this predis-
position at both the population and molecular genetic
levels are poorly understood at present. Progress is,
however, being made both through the study of the
population genetics of families with high incidences of
breast cancer and the cytogenetic and molecular char-
acterization ofhuman breast carcinomas. For example,
we recently cytogenetically characterized a large series
of untreated human breast carcinomas and found 3 of
44 with clonalkaryotypic changes. A young womanwith
bilateral carcinomas had a 3p deletion in one tumor,
while two other tumors had transitions involving chro-
mosome 1 (1). It has been suggested that these sorts of
chromosomal changes are associated with the loss of
suppressor gene activity or the activation of certain
oncogenes (2).
Mostofthe suppressor genesand oncogenesthathave
been identified in human tumors have been largely con-
served through eukaryotic evolution. Based on this, we
are attempting to identify genes that modulate human
breast carcinogenesis by characterizing potential hom-
ologues in lower mammals. We chose this path of in-
vestigation because of the relative ease of genetically
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characterizing species that can be both selectively and
rapidlybred. Theanimalmodelchosenwastherat, with
many inbred strains available for study. The rat was
chosen over the mouse because a) mammary cancers in
the rat, like the human but unlike the mouse, lack a
major viral etiology, b) tumors of the rat, unlike the
mouse, are readily induced by chemicals, radiation, or
hormonal treatments, and c) the rat mammary tumor
resembles that ofthe human in its spectra ofhormonal
responsiveness. Unfortunately, the rat has a much less
characterized genomic map than does the mouse.
Rat Strain Susceptibility
Rattypes (outbred) and strains(inbred) differintheir
susceptibilities to both spontaneous and induced mam-
mary cancers. We have recently reviewed the suscep-
tibility ofmany rat strains to spontaneous and induced
mammary tumors (3). The susceptibility ofa rat strain
to spontaneous carcinomas cannot be predicted by its
susceptibility to induced cancer. In previously review-
ing the incidence of various spontaneous tumors in dif-
ferent rat strains, we found a strong correlation be-
tween the propensity of a specific strain to develop
prolactin-secreting pituitary tumors and its likelihood
to develop mammary carcinomas (3). This association is
mechanistically reasonable, since prolactin has been
shown to be apromoter ofratmammary carcinogenesis
(4,5). Thus, increased susceptibility to spontaneous
mammary cancer is probably controlled via an abscopal
mechanism related to hyperplastic and neoplasticGOULD AND ZHANG
changes in the prolactin-secreting cells of the anterior
pituitary. The propensity of a rat to develop pituitary
cell transformation is genetically controlled in an ad-
ditive fashion by approximately three independently
segregating genes (6).
In general, rat strains fall into three susceptibility
groups for the development of induced mammary car-
cinomas. The first group has a high incidence oftumors
followingcarcinogen administration (e.g., Wistar-Furth
[WF]), while the second is totally resistant (e.g., Co-
penhagen [Cop]). The third group, which includes the
Fischer (F344) rat, has an intermediate susceptibility
(Figs. 1 and 2). We determined the genetic basis for
these three categories of rats by segregation analysis.
WF ratsfromthehighsusceptibilitygroupofratstrains
were bred to F344 rats from the intermediate suscep-
tibility group of strains. We tested parent strains as
well as F1, F2, and backcross rats for the development
ofmammary carcinomasfollowingexposuretothemam-
mary carcinogen 7,12-dimethylbenz[a]anthracene
(DMBA). We found that each group ofhybrid rats was
phenotypically very similartothe more susceptible par-
entstrain, theWF rat (7) (Fig. 1). Thesedatasuggested
that the susceptibility-conferring factor in the WF rat
was controlled by multiple, independently segregating
genes. The action of these genes was not additive, in
that rats with one or more of these genes had equal
susceptibility to DMBA-induced mammary tumors.
When various genetic models were fit to the data, we
found that the one suggesting three independently seg-
regating genes fit best. Further experiments in which
the sexes of the strains in the analysis were reversed
suggested that these genes werenot sexlinked and that
maternal factors orgenetic imprinting was not a factor.
Whethereachindependently segregatingsusceptibility-
conferring gene is the same or different remains to be
determined.
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FIGURE 1. Time to first mammary tumor of rats given DMBA (130
mg/kg) at zero time. Rat strains include the parent strains WF
and F344 and specific crosses: WF x F344 F1; backcross F344 x
(F1); backcross WF x (F1); and F2(F1 x F1, F1 = WF x F344).
The genetic composition of rats in the second cate-
gory, which are completely resistant to both induced
and spontaneous mammary tumors, was also tested by
segregationanalysis. ResistantCopratswerebredwith
susceptible WF rats. Parent strains, F1, F2, and back-
crosshybridratsweretreatedwithDMBAandfollowed
for the development of mammary carcinomas (Fig. 2).
The results ofthis analysis suggest that the resistance
to mammary carcinogenesis found in the Cop rat is due
to a single autosomal dominant gene (3). A similar con-
clusion was reached by Isaacs, who crossed and tested
progeny of Cop and Sprague-Dawley rats (8). We have
termed this Cop rat gene the mammary carcinoma sup-
pressor or MCS gene (9). Thus, we conclude that rats
in the high susceptibility category, such as the WF,
possess one or more susceptibility-conferring genes,
while rats in the most resistant category, such as the
Cop, carry a suppressor gene (MCS). Rat strains such
as F344 that show an intermediate susceptibility to in-
duced mammary cancer contain neither gene. Finally,
when animals that contain both genes are bred (e.g.,
WF x Cop F1), the offspring exhibit a resistant phen-
otype (Fig. 2) (3).
Site of Expression
In orderto begin to characterize the function ofthese
genes as well as to develop strategies to clone them, we
soughttodeterminetheirorgan/tissuesiteofexpression
and action. We approached this question for both the
susceptibility (7) and MCS genes (9) by constructing
andtestingchimericrats. Chimericratsareconstructed
by grafting known numbers of clonogenic mammary
cells from donor rats to ectopic sites such as the inter-
scapular white fat pad of recipient rats (10). Here the
clonogenic cells divide and redifferentiate to structur-
ally and functionally normal mammary tissue (11). In
these assays, the recipient rats are usually F1 hybrids
oftwo inbred strains. Thus, it is possible to graft tissue
from either parent strain into the F1 recipient rats.
To determine if the susceptibility genes carried by
the WF ratare active withinthemammaryparenchyma
or abscopally active such as in the immune or endocrine
system, WF-F344 chimerics were constructed and
tested. WF x F344 F1 hybrids received ectopic mam-
marygrafts from either F344 orWF rats. Afterectopic
glands differentiated from these transplanted cells, the
recipient hybrid rats were given DMBA, and tumors
developing in the ectopic sites were followed by weekly
palpation. If the WF susceptibility genes were active
in host systems such as the endocrine system, then it
would be predicted that both F344 and WF ectopic
mammary glands should develop equal numbers of tu-
mors since they developed in identical F1 hosts. On the
other hand, ifthe WF susceptibility genes were active
withinthemammaryparenchyma, thenitwouldbepre-
dicted that more carcinomas should develop in the WF
ectopic glands. The results supported the latter predic-
tion, in that more tumors developed in the WF ectopic
glands when compared to equivalent ectopic F344
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FIGURE 2. Segregation analysis of the gene conferring resistance to mammary carcinogenesis in the Cop rat. Groups of approximately 25
female rats ofeach parent strain or cross listed in the figure were fed DMBA (130 mg/kg) and followed for tumors. The percentage of rats
developing mammary tumors over time is shown in the figure.
Weeks Post DMBA
FIGURE 3. Chimeric rats with interscapular grafts ofWF (a) orF344
(0) mammary glands were fed DMBA at zero time. The time and
percentages of rats that developed mammary carcinomas at the
graft sites are plotted.
glands (Fig. 3). Thissuggests thattheWF susceptibility
gene mediates its effects within the mammary paren-
chyma.
A similar approach was taken to identify the site of
action of the Cop MCS gene. In an initial experiment,
WF cells were grafted into either WF x Cop or WF
x F344 recipient rats. These rats were then treated
with DMBA and followed for tumors developingin both
grafted and in situ mammary glands. This design dif-
fered from the one used above to characterize the sus-
ceptibility gene because, if Cop cells were grafted into
WF x Cop and no tumors arose, one could not deter-
mine ifthis was the effect ofthe Cop gene in the mam-
mary cell or in the host. It was predicted that if the
MCS gene was only active within the mammary par-
enchyma, then equal numbers of mammary carcinomas
would develop in the ectopic WF grafted mammary
glands in the two types ofhybrid host, even though the
WF x F344 hybrid would develop amuch greater num-
ber of mammary tumors in its in situ mammary glands.
On the other hand, if the MCS gene was expressed in
a nonmammarytissue, such as the endocrine orimmune
system, then it would be expected that fewer tumors
would develop in the WF ectopic mammarygland inthe
WF x Cop host than in the WF x F344 host. Fur-
thermore, the ratio of tumors in the WF graft sites of
these hybrid hosts should be the same as the ratio of
mammary carcinomas developing in their respective in
situ glands. The results obtained were not in complete
agreement with either prediction. The ratio of tumors
intheinsitu mammaryglandsoftheWF x F344 versus
the WF x Cop hosts was 10:1. The ratio of tumors
developing in the WF ectopic glands in these two hosts
was 2:1 (Fig. 4). These data suggest that the main sup-
pressor activity associated with the Cop rat resides in
the mammary parenchyma. However, a small amount
ofsuppressor activity is also expressed abscopally. This
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FIGURE 4. Comparison ofthe ratio of average number ofcarcinomas
in in situ and graft site mammary glands. The ratio of average
number of host mammary tumors in the WF x F344 versus WF
x Cop rats is 10 to 1, while at graft sites the ratio of tumors is
2 to 1. Bars representthe mean numbers obtainedfromeach group
± SE. WF x F344 (M, n = 99); WF x Cop (E], n = 122). From
Zhang et al. (9).
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FIGURE 5. Comparison ofthe mammary carcinomas at ectopic sites
grafted with mammary cells from different rat strains. Bars rep-
resent the mean numbers ofcarcinomas ofeach group ± SE. WF
donor cells grafted into WF x Cop (O, n = 122); Cop donor cells
grafted into WF x Cop (U, n = 90); a 1:1 mixture ofWF and Cop
donor cells grafted into WE x Cop (1, n = 74). From Zhang et
al. (9).
lesser activity may be due to the expression ofthe MCS
gene product at locations outside the mammary par-
enchyma. Alternatively, it may be due to another Cop
gene with a minor suppressor activity that was missed
in our segregation analysis due to its low penetrance.
We plan to check these alternative explanations by con-
ducting similar experiments in MCS-carrying WF co-
genic rats that are currently being bred.
To confirm that the MCS gene was indeed highly
active within the mammary epithelium, a second ex-
periment wasconducted. Here eitherCop orWF ectopic
glands were grafted into identical WF x Cop F1 hybrid
recipients. The numbers of carcinomas arising in the
graft sites were quantitated and compared (Fig. 5).
Many tumors developed in the WF glands, while only
a single carcinoma was detected in the Cop glands.
These data support the above conclusion that the MCS
gene product is functional within the mammary par-
enchyma.
Gene Function
The ratMCS gene is organ-specific inits action. Dun-
ning and Curtis showed that the chemical carcinogens
whose action was suppressed in the Cop mammary
gland could cause tumors in other organs such as the
liver in this rat strain (12). We extended these obser-
vations by investigating the activity of the Cop MCS
gene in inhibiting various DMBA-induced epithelial
pathologies in the rat mammary gland. In the experi-
ments described above, our results were based on the
developmentofpalpablecarcinomas atthe ectopicmam-
mary graft sites. DMBA-exposed graft sites not devel-
oping carcinomas were prepared for whole mount ob-
servation. Lesions found in the whole mounts were
removed and sectioned forhistopathological study. Two
nonpalpable epithelial lesions were found. These were
small mammary carcinomas termed microcarcinomas
(Fig. 6) and focal alveolar hyperplasias (FAH) (Fig. 7).
LesionswerecomparedinDMBA-treatedWF ectopic
mammary glands growing in WF x F344 versus those
growing in WF x Cop hybrid recipient rats. We found
equal frequencies of microcarcinomas in WF glands in
both recipient types (Fig. 8), indicating that the MCS
gene does not affect microcarcinomas at the host level.
However, when Cop cells were grafted intoWF x Cop,
nomicrocarcinomas werefound (Fig. 9). Togetherthese
data suggest that the MCS gene inhibits the develop-
ment of microcarcinomas and that its action in this re-
gard is totally mediated within the mammary paren-
chyma (9).
In contrast to the activity of the MCS in inhibiting
microcarcinomas, we found that this gene had no influ-
ence on the development of FAH. We compared the
frequency ofFAH developing in DMBA-treated ectopic
WF and Cop mammary glands growing in WF x Cop
hosts. No statistically significant difference was found
in the frequencies of FAH developing in Cop and WF
glands (9) (Fig. 9).
We next asked if the MCS gene product acted in a
paracrine manner, with theMCS gene product secreted
by the mammary cells into the extracellular space fol-
lowed by binding ofthe MCS product to mammary cell
surface receptors. Such aparacrine mechanismhasbeen
demonstrated in human mammary tumors for growth
factors such as transforming growth factor x and ,B (13).
This question was approached by establishing a mixed
cell mammary gland that contained equal numbers of
WF and Cop mammary cells. These mixed glands as
well as WF and Cop nonmixed control glands were ex-
posed to DMBA and the development of graft site car-
cinomas compared. The mixed cell and WF glands did
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FIGURE 6. Histopathology of DMBA-induced mammary alveolar hyperplasia. (a) Whole mount of fat pad containing a focal lesion indicated
by an arrow; (b) 5 x magnification of this focal lesion; and (c) histopathological section of this lesion. From Zhang et al. (9).
not significantly differ in the frequency of carcinomas
formation, while both frequencies were much greater
than that found in the Cop mammary ectopic glands
(Fig. 5). These results indicate that the presence ofCop
cells did not modulate the susceptibility ofneighboring
WF cells to DMBA-induced carcinogenesis. Thus, the
MCS gene product does not act intercellularly.
We have also begun to ask at which stage in carcino-
genesis do the susceptibility and MCS genes act. Thus
far, we have examined the very early stages ofDMBA
carcinogenesis: carcinogen activation and DNA adduc-
tion. Both these processes were studied in primary cul-
tures ofmammary epithelial cells to avoid anyconfound-
ing systemic effects, since we knew that both classes of
genes are mainly active within the mammary paren-
chyma.
Radiolabeled DMBA was added to WF, F344, and
Copratmammarycellcultures. DMBAmetabolites that
were released into the medium were collected, isolated,
and analyzed by reverse-phase HPLC. No qualitative
or quantitative differences were found in DMBA me-
tabolism in mammary cultures of these three strains
(14). Next, DNA wasisolated from DMBA-treated cells
and assayed for DMBA-DNA adducts. Again, no qual-
itative or quantitative differences between cultures
from these three strains of rats were found (14). This
suggests that it is likely that both the susceptibility and
MCS genes act at carcinogenesis stages beyond DNA
adduction.
Conclusions and Future Directions
In summary, we have found that various inbred rat
strains differintheirsusceptibilities to spontaneous and
induced mammary carcinomas. The rate ofspontaneous
mammary carcinomas can be increased by genes acting
within the pituitary that cause hyperplasia and neopla-
sia of the prolactin-producing cells. In contrast, spon-
taneous mammary carcinogenesis can be totally inhib-
ited by the MCS gene, which acts mainly within the
mammary epithelium. This gene also inhibits radiation,
chemical, and hormone-induced mammary carcinomas.
In rats lackingthe MCS gene, the frequency ofinduced
mammary carcinoma can be increased by dominant sus-
ceptibility genes acting within the mammary paren-
chyma. The susceptibility and MCS genes act at stages
of carcinogenesis beyond carcinogen activation and
DNA adduction.
TheMCS geneismammarycarcinoma-specific inthat
it does not inhibit induced or spontaneous tumors in
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FIGURE 7. Histopathology of DMBA-induced mammary microcarcinoma. (a) Whole mount offat pad containing a focal lesion indicated by an
arrow; (b) 5 x magnification ofthis focal lesion; and (c) histopathological section of this lesion. From Zhang et al. (9).
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FIGURE 8. Average number of palpable and microcarcinomas de-
veloping at graft sites of WF mammary cells in different host
strains. Bars represent mean values of each group ± SE. WF
donor cells grafted into WF x Cop (Ol, n = 122); WF donor cells
grafted into WF x F344 (1, n = 99). From Zhang et al. (9).
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other organs tested and also does not inhibit noncarci-
noma carcinogen-induced pathologies within the mam-
mary gland.
We are currently attempting to further characterize
the function ofboth the susceptibility and MCS genes.
For example, we and others have been unable to induce
mammary carcinomas in Cop rats by a wide variety of
physical, chemical, and hormonal carcinogens. We are
currently attempting to overcome thisMCS-induced re-
sistance by introducing a series of activated oncogenes
into the mammary epithelium ofCop and control strain
rats. Definingoncogenes that can and cannot bypass the
suppressor function ofthe MCS gene will aid us in un-
derstanding the mechanism ofMCS action. Finally, we
are also currently involved in devising strategies to mo-
lecularly clone and characterize the MCS gene. We are
currently evaluating both subtraction hybridization and
insertional mutagenesis as a means to achieve this goal.
We thank Cynthia Moore for reviewing the manuscript and Peggy
Ziebarth forits preparation. This work was supported by PHS, NIH,
NCI grant CA28954.
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